Introduction {#onco12107-sec-0001}
============

Progress in the fight against cancer has relied heavily on evidence generated from clinical trials, representing the experience of less than 5% of all newly diagnosed cancer patients \[[1](#onco12107-bib-0001){ref-type="ref"}\]. Older adults (age 65+ years) are disproportionately affected by this trial‐driven research paradigm, as they are less likely than younger patients to be enrolled onto clinical trials \[[1](#onco12107-bib-0001){ref-type="ref"}\], \[[2](#onco12107-bib-0002){ref-type="ref"}\] despite accounting for the majority of cancer‐related morbidity and mortality in the United States \[[3](#onco12107-bib-0003){ref-type="ref"}\].

National efforts led by the American Society of Clinical Oncology (ASCO), the National Cancer Institute, the Food and Drug Administration, and most recently by former Vice President Joe Biden and the Cancer Moonshot initiative, have promoted data linkage and data sharing as a means to capture patient information and outcomes outside of clinical trials to accelerate progress in the fight against cancer. In a recent position statement on improving the evidence base for treating older adults \[[4](#onco12107-bib-0004){ref-type="ref"}\], ASCO recommended developing a robust research infrastructure outside of clinical trials using observational methods and collection of relevant geriatric oncology‐specific information alongside other patient, tumor, and treatment data.

To demonstrate the feasibility of building such a resource for geriatric oncology, we linked information from a sample of older adults with cancer in North Carolina using three distinct data sources.

Materials and Methods {#onco12107-sec-0002}
=====================

The Carolina Senior Registry (NCT01137825) is a hospital‐based cancer registry including one academic and seven community sites, started in 2009 to collect data from a brief geriatric assessment performed on older adults living with cancer \[[5](#onco12107-bib-0005){ref-type="ref"}\], modeled after the tool developed by Hurria and colleagues \[[6](#onco12107-bib-0006){ref-type="ref"}\]. Geriatric assessment data were collected through healthcare provider evaluation (performed by the treating oncologist or trained clinical research assistant) and patient‐administered questionnaires. The current study is limited to patients treated at the one academic site, accounting for 69% of all patients in the Carolina Senior Registry, as all required data elements for the linkage were readily available.

Using patients' first and last name, date of birth, sex, and hashed social security number, we applied deterministic and probabilistic linkage algorithms to patients in the Carolina Senior Registry and the North Carolina Central Cancer Registry (NCCCR), which captures tumor information legally reportable by all healthcare providers in North Carolina. We then used a crosswalk developed by UNC Lineberger Integrated Cancer Information and Surveillance System researchers to map patients in the NCCCR to the Medicare enrollment database \[[7](#onco12107-bib-0007){ref-type="ref"}\]. Medicare fee‐for‐service claims capture longitudinal information about beneficiaries' healthcare encounters, including diagnoses and procedures from hospitalizations and outpatient visits.

Figure [1](#onco12107-fig-0001){ref-type="fig"} provides an overview of the information contributed by each data source. Analyses were conducted using SAS version 9.4 (Cary, North Carolina). Descriptive statistics for the cohort are presented. This study was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill.

![Patient information contained in each of the three data sources used in the linkage feasibility study of older adults with cancer in North Carolina.\
Abbreviations: ER, emergency room; NC, North Carolina; NCCCR, North Carolina Central Cancer Registry.](onco12107-fig-0001){#onco12107-fig-0001}

Results {#onco12107-sec-0003}
=======

Of the 703 older cancer patients in the Carolina Senior Registry, we linked 636 patients (90%) to the NCCCR and 546 (78%) to the Medicare enrollment database. Among this population, 369 (68%) were continuously enrolled in Medicare Parts A and B (without managed care enrollment) for 6 months prior to the geriatric assessment date. Characteristics of the study population stratified by claims‐based Charlson comorbidity score \[[8](#onco12107-bib-0008){ref-type="ref"}\] are reported in Table [1](#onco12107-tbl-0001){ref-type="table"}.

###### Characteristics of sample of older adults, overall and by Charlson Comorbidity Index

![](onco12107-tbl-0001){#nlm-graphic-5}

Indicates that missing values were added to this category.

Abbreviations: --, at least one cell size was less than 11 and therefore had to be suppressed for confidentiality; AJCC, American Joint Commission on Cancer; BOMC, Blessed Orientation Memory Concentration test; CCI, Charlson Comorbidity Index; KPS, Karnofsky Performance Score; GA, geriatric assessment; IQR, interquartile range; MHI, Mental Health Index; TUG, Timed‐Up and Go.

The study population primarily includes women, driven largely by overrepresentation of early‐stage breast cancer patients seen by recruiting oncologists. Median age was 74 years, and more than half of the population had some college education. The prevalence of patients with unintentional weight loss, prolonged Timed‐Up and Go (less than14 seconds, indicating poor mobility), or a physician‐rated Karnofsky Performance Status of less than 80% steadily increased with a higher Medicare claims‐based Charlson comorbidity score. However, the prevalence of patients with polypharmacy (9+ medications) or a Blessed Orientation Memory Concentration test score of less than 11 (suggestive of memory impairment) did not monotonically increase with higher Charlson comorbidity score. These preliminary results demonstrate how linked data resources enrich our ability to identify important variation in health status among older adults with cancer that cannot be described using a singular measure.

Discussion {#onco12107-sec-0004}
==========

We demonstrated the feasibility of linking information from three disparate but complimentary data sources for a sample of older adults with cancer treated at a North Carolina academic medical center. This data resource richly characterized the health status and tumor features of older adults living with cancer and established a mechanism to identify specific treatments administered and conduct passive surveillance and longitudinal follow‐up using Medicare enrollment and claims data. As cancer treatment regimens become increasingly complex, both regulators and patient advocacy groups want to better understand the impact of treatment on patient‐centered geriatric oncology outcomes (e.g., emergency department visits, nursing home placement, decline in physical function, memory impairment), which are not traditionally captured in clinical trials. Therefore, linkage of rich but disparate data sources represents a promising avenue to capture more multifaceted outcome measures.

Other groups have launched research initiatives to improve the evidence base for treating older adults with cancer or collect real‐world data on cancer patients outside of the trial setting. For example, the Cancer and Aging Research Group has undertaken numerous studies collecting geriatric assessment data on patients from multiple medical centers \[[9](#onco12107-bib-0009){ref-type="ref"}\]. However, these data have not yet been linked to state cancer registries or Medicare, Medicaid, or other insurance claims data, limiting their ability to passively follow patients over time. On the other hand, researchers within the Cancer Research Network have developed a robust infrastructure for pooling electronic health record data for cancer patients across multiple integrated healthcare delivery systems \[[10](#onco12107-bib-0010){ref-type="ref"}\], but detailed geriatric assessment data are not routinely collected for older patients with cancer in these settings.

Conclusion {#onco12107-sec-0005}
==========

While the research questions that can be explored using the linked Carolina Senior Registry data are limited by the small sample and limited generalizability at present, we plan to partner with institutions interested in conducting similar linkages in order to build a larger database well‐suited to address a variety of questions regarding the care of older adults with cancer. In the future, large, linked data sources can be used to fill existing evidence gaps regarding long‐term benefits and harms of cancer treatments, and ultimately to tailor the delivery of cancer care and improve outcomes for older adults with cancer.
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